Posted on Jul 02, 2019
The drug company Sandoz Inc., makers of Ranitidine Hydrochloride Capsules 150mg and 300 mg (Zantac), has issued a voluntary recall after confirming that the generic Zantac capsules contained an “unexpected impurity, N-Nitrosodimethylamine (NDMA),” which is a probably human carcinogen.
The U.S. Food and Drug Administration issued an advisory on Sept. 13, 2019, warning the public of a Zantac cancer risk due to chemical contamination of the heartburn medication.
The FDA explained that medicines containing ranitidine, including Zantac (ranitidine), contain trace amounts of n-nitrosodimethylamine (NDMA). Laboratory tests have demonstrated NDMA to be a potent carcinogen.
Although one drug company has stopped distribution of its generic version and the Connecticut pharmacy where the contamination was first discovered has petitioned the FDA to issue a recall, there are no plans at this time to remove existing product from pharmacy shelves at this time.
FDA officials are saying that people may continue to take Zantac and other ranitidine medications, but those who are on a prescription version should consult with their physicians in order to find out if an alternative treatment is available.
If you or a loved one took Zantac and went on to develop stomach cancer or bladder cancer, you may qualify to join this Zantac cancer lawsuit investigation.
Reports are coming in across the country of lung disease and other hidden health risk associated with the popular vape JUUL
Oct 02, 2019
CNN Reports on the latest of three massive verdicts in favor of the plaintiffs for Round Up
May 14, 2019